A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells

This publication has 48 references indexed in Scilit:

• Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer
  Cancer Research, 2009
• The Anti-Cancer Activity of Noscapine: A Review
  Recent Patents on Anti-Cancer Drug Discovery, 2009
• Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient?
  Clinical Cancer Research, 2007
• Effective chemotherapy for hormone-refractory prostate cancer (HRPC): Present status and perspectives with taxane-based treatments
  Critical Reviews in Oncology/Hematology, 2007
• Treatment of hormone-refractory breast cancer: apoptosis and regression of human tumors implanted in mice
  Molecular Cancer Therapeutics, 2006
• Synthesis of microtubule-interfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell death
  Biochemical Pharmacology, 2006
• Noscapine inhibits hypoxia-mediated HIF-1α expression andangiogenesis in vitro: a novel function for an old drug
  International Journal of Oncology, 2006
• Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo
  The Prostate, 2005
• Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells
  Proceedings of the National Academy of Sciences, 1998
• New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
  JNCI: Journal of the National Cancer Institute, 1990